Abstract
Few studies have examined the treatment of molecular relapse in patients with acute myeloid leukemia (AML) using different treatment regimens. We describe for the first time in the literature experiences with administration of clofarabine monotherapy in the treatment of eight patients with AML with molecular relapse of the disease.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine Nucleotides / pharmacology
-
Adenine Nucleotides / therapeutic use*
-
Adult
-
Aged
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Arabinonucleosides / pharmacology
-
Arabinonucleosides / therapeutic use*
-
Clofarabine
-
Drug Administration Schedule
-
Female
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / genetics
-
Leukemia, Myeloid, Acute / mortality
-
Leukemia, Myeloid, Acute / pathology
-
Male
-
Middle Aged
-
Mutation
-
Nuclear Proteins / genetics
-
Nucleophosmin
-
Oncogene Proteins, Fusion / genetics
-
Recurrence
-
Remission Induction
-
Survival Analysis
-
Treatment Outcome
Substances
-
Adenine Nucleotides
-
Antineoplastic Agents
-
Arabinonucleosides
-
Nuclear Proteins
-
Oncogene Proteins, Fusion
-
Nucleophosmin
-
Clofarabine